Quest Diagnostics Incorporated (DGX) Financial Statements (2026 and earlier)

Company Profile

Business Address 500 PLAZA DRIVE
SECAUCUS, NJ 07094
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments420432319188549764
Cash and cash equivalent420432319188549764
Receivables1,4081,4561,4191,4041,3041,376
Inventory, net of allowances, customer advances and progress billings189186187189188184
Inventory189186187189188184
Prepaid expense 32   47 
Other undisclosed current assets329333273294304299
Total current assets:2,3782,4072,1982,0752,3922,623
Noncurrent Assets
Operating lease, right-of-use asset657649655656651661
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization2,2032,1452,1202,0982,1132,093
Long-term investments and receivables136137136134123125
Long-term investments136137136134123125
Intangible asset, including goodwill, after accumulated amortization10,58110,56310,58910,57410,61910,321
Goodwill8,9458,9018,8838,8498,8568,605
Intangible asset, excluding goodwill, after accumulated amortization1,6361,6621,7061,7251,7631,716
Other noncurrent assets270296271260255272
Total noncurrent assets:13,84713,79013,77113,72213,76113,472
TOTAL ASSETS:16,22516,19715,96915,79716,15316,095
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,6001,4571,3491,2671,3941,313
Accounts payable 307   287 
Accrued liabilities 338   306 
Other undisclosed accounts payable and accrued liabilities9551,4571,3491,2678011,313
Debt5075045041603603
Other undisclosed current liabilities171173171173172176
Total current liabilities:2,2782,1342,0241,4412,1692,092
Noncurrent Liabilities
Long-term debt and lease obligation, including:5,1675,1715,1695,8585,6155,648
Long-term debt, excluding current maturities 5,167   5,6155,648
Finance lease, liability 18   16 
Other undisclosed long-term debt and lease obligation(18)5,1715,1695,858(16) 
Liabilities, other than long-term debt1,4941,5161,4301,4551,4731,434
Other liabilities957982890917938891
Operating lease, liability537534540538535543
Total noncurrent liabilities:6,6616,6876,5997,3137,0887,082
Total liabilities:8,9398,8218,6238,7549,2579,174
Temporary equity, including noncontrolling interest808181818380
Equity
Equity, attributable to parent7,1707,2587,2286,9296,7786,809
Common stock222222
Treasury stock, value(5,180)(4,896)(4,772)(4,790)(4,857)(4,732)
Additional paid in capital2,3812,3552,3322,3102,3612,332
Accumulated other comprehensive loss(27)(40)(16)(83)(88)(15)
Retained earnings9,9949,8379,6829,4909,3609,222
Equity, attributable to noncontrolling interest363737333532
Total equity:7,2067,2957,2656,9626,8136,841
TOTAL LIABILITIES AND EQUITY:16,22516,19715,96915,79716,15316,095

Income Statement (P&L) ($ in millions)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues2,8062,8162,7612,6522,6212,488
Cost of revenue(1,896)(1,867)(1,818)(1,789)(1,763)(1,677)
Gross profit:910949943863858811
Operating expenses(541)(540)(525)(515)(503)(480)
Other operating income (expense), net17(23)20(2)6(1)
Operating income:386386438346361330
Nonoperating expense(56)(58)(54)(70)(62)(34)
Other nonoperating income (expense)8813(3)315
Income from continuing operations before equity method investments, income taxes:330328384276299296
Income from equity method investments7891856
Income from continuing operations before income taxes:337336393294304302
Income tax expense(81)(77)(97)(59)(68)(65)
Net income:256259296235236237
Net loss attributable to noncontrolling interest(11)(14)(14)(15)(14)(11)
Net income available to common stockholders, basic:245245282220222226
Other undisclosed net income (loss) available to common stockholders, diluted4(2)(1)(1)3(1)
Net income available to common stockholders, diluted:249243281219225225

Comprehensive Income ($ in millions)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income:256259296235236237
Other comprehensive income (loss)13(24)675(73)4
Comprehensive income:269235363240163241
Comprehensive loss, net of tax, attributable to noncontrolling interest(11)(14)(14)(15)(14)(11)
Comprehensive income, net of tax, attributable to parent:258221349225149230

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: